Midostaurin in Advanced Systemic Mastocytosis: A Systematic Review and Meta-analysis

Affiliations

¹ Department of Internal Medicine, University of Toledo, Toledo, OH.
² Division of Hematology and Oncology, Department of Internal Medicine, University of Toledo, Toledo, OH.
³ Division of Pulmonology and Critical Care Medicine, Department of Internal Medicine, University of Toledo, Toledo, OH.

Meta-Analysis

Ziad Abuhelwa et al. Am J Ther. 2023 Nov-Dec.

. 2023 Nov-Dec;30(6):e573-e575.

doi: 10.1097/MJT.0000000000001508. Epub 2022 Apr 21.

¹ Department of Internal Medicine, University of Toledo, Toledo, OH.
² Division of Hematology and Oncology, Department of Internal Medicine, University of Toledo, Toledo, OH.
³ Division of Pulmonology and Critical Care Medicine, Department of Internal Medicine, University of Toledo, Toledo, OH.

No abstract available

Conflict of interest statement

The authors have no conflicts of interest to declare.

1. Pardanani A. Systemic mastocytosis in adults: 2021 Update on diagnosis, risk stratification and management. Am J Hematol. 2021;96:508–525.
1. Reiter A, George TI, Gotlib J. New developments in diagnosis, prognostication, and treatment of advanced systemic mastocytosis. Blood. 2020;135:1365–1376.
1. Chandesris MO, Damaj G, Lortholary O, et al. Clinical potential of midostaurin in advanced systemic mastocytosis. Blood Lymphat Cancer. 2017;7:25–35.
1. Ustun C, Reiter A, Scott BL, et al. Hematopoietic stem-cell transplantation for advanced systemic mastocytosis. J Clin Oncol. 2014;32:3264–3274.
1. Kasamon YL, Ko CW, Subramaniam S, et al. FDA approval summary: midostaurin for the treatment of advanced systemic mastocytosis. Oncologist. 2018;23:1511–1519.